Daily FNArena News - Australia

Despite uncertainty following the Royal Commission, a more immediate funding response is expected to find its way to the listed providers, and likely boost FY21 earnings

A slump in plasma collections as a result of pandemic-induced lockdowns has put the share price of CSL under pressure. With a vaccine roll-out is it time to buy?

A vaccine, re-opening of domestic borders and a tourism support package are stimulating renewed interest in Qantas. How will this play out for a return to profit?

While bonds yields have risen on higher inflationary expectations, driven by higher commodity prices and expectations surrounding large US fiscal stimulus, the big unknown is what will happen next?

A divestment process in the Americas has started as Treasury Wine aims for a leaner, more profitable business, but where will growth come from?

Despite the constraints created by a shortage of new cars, robust used car prices have ensured Eclipx can deliver substantial earnings growth

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

As the outlook for minerals exploration improves and concerns over the economic impact of the pandemic ease, the laboratory services of ALS Ltd will be in demand

Can a revived order book and the transition of its business model turnaround near-term uncertainty and any reputational damage overhanging shipbuilder Austal?

Improved farm income from bumper crops is good news for Elders, while livestock & wool conditions should also contribute to earnings growth